TaiGen Biotechnology
0
0
0
About
Overview
Steering Committee
Career
Management Team
Milestones
Board of Directors
About Us
TaiGen is a discovery-based and market-focused pharmaceutical company engaging in the development of novel therapeutics for infectious diseases and other indications with high degree of unmet medical needs.
R&D Center
Pipeline
R&D Progress
Antibiotic
Taigexyn®
Influenza Antiviral
Pixavir (TG-1000)
HIF-PHD Inhibitor
ISM-4808
Dipeptidyl Peptidase 1 (DPP1) Inhibitor
TG-4318
Stem Cell Mobilizer
Burixafor
HCV Antiviral
Furaprevir
Research
R&D Center
TaiGen’s dedicated team of professional scientists perform cutting edge research in drug discovery to advance programs efficiently. Our pipeline of anti-infective & anti-inflammatory programs are the fruits of both internal research as well as in-licensed programs.
News
News
Investors
Investors
Financial Information
Material Information
Material Information
Shareholders' Information
Shareholders' Information
Corporate Governance
Investor FAQs
Investors
Communicating with investors, cultivating long-term investor relations and highlighting corporate’s value.
Business & Partnership
ESG
Contact Us
Home
繁中
ESG
ESG
Stakeholders
ESG Report
2024 Sustainability Report
2023 Sustainability Report
Home
ESG
ESG Report
